Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada the United States Israel Switzerland and Australia. In 2011 the manufacturers made a decision to cease promotion manufacturing distribution and sales of Amevive during a supply disruption. According to Astellas Pharma US Inc.
ATC prefix
L04
ATC suffix
AA15
Bioavailability
63.0
CAS number
222535-22-0
DrugBank
DB00092
FDA UNII code
ELK3V90G6C
IUPAC name
1-92-LFA-3 (Antigen) (human) fusion protein with immunoglobin G1 (human hinge CH2-CH3γ1-chain) dimer
This page contains content from the copyrighted Wikipedia article "Alefacept"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.